You are here: Industry Insights > Stivarga

News List

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement worldpharmanews
July 19, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement.
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial worldpharmanews
June 24, 2019
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial.
NICE approves Bayer’s liver cancer drug pharmaphorum
November 30, 2018
NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug......
Bayer’s Stivarga wins NICE backing for advanced liver cancer pharmatimes
November 29, 2018
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year which rejected the drug.
EU approved Bayer's Stivarga for the Second-Line Systemic Treatment of Liver Cancer firstwordpharma
August 08, 2017
The approval for the first treatment advance in nearly 10 years is based on data from the Phase III RESORCE research.
FDA awards priority review to Bayer's filing for Stivarga as second-line liver cancer treatment firstwordpharma
January 05, 2017
Bayer on Wednesday said the FDA granted priority review to an application seeking approval of Stivarga (regorafenib) for the second-line treatment of patients with hepatocellular carcinoma (HCC).